JK-102-CA (SM-102 Analogue)

Please contact us at sales@jenkemusa.com for a quote for large scale GMP manufacture of  JK-102-CA (SM-102 Analogue).


JenKem Technology provides large scale GMP manufacture of JK-102-CA (SM-102 Analogue) with high purity (97%, and higher) for commercial pharma applications and clinical trials. JK-102-CA (SM-102 Analogue) is a high-quality reagent for Lipid Nanoparticles (LNPs).

LNP drug delivery systems are commonly employed for nucleic acid delivery. LNPs are generally believed to combine with the cell membrane through noncovalent affinity and absorbed by endocytosis. After being absorbed by the cell, the mRNA delivered by LNPs are released to the cytoplasm and express the target protein, escaping from the endocytosis. This technology has been adopted by pharmaceutical companies in the recent years for COVID-19 vaccine manufacture1.

Please visit https://www.jenkemusa.com/products-for-lnps-and-rna-delivery to learn about our PEG and small molecule product line for LNPs. Please contact us at sales@jenkemusa.com for a quote for large scale GMP manufacture of  JK-102-CA (SM-102 Analogue).

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high-quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified and adheres to ICH Q7 guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.


  1. Zhang, L., et al., Controlled production of liposomes with novel microfluidic membrane emulsification for application of entrapping hydrophilic and lipophilic drugs, Journal of Industrial and Engineering Chemistry, 131, 2024, p.470-480.
  2. Schoenmaker, Linde, et al., mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability, International Journal of Pharmaceutics 601 (2021)
Go to Top